Islet antibodies and remaining beta-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide Diabetes Incidence Study in Sweden.
(2004) In Journal of Internal Medicine 255(3). p.384-391- Abstract
- Objectives. To establish the prevalence of remaining beta-cell function 8 years after diagnosis of diabetes in young adults and relate the findings to islet antibodies at diagnosis and 8 years later.
Design. Population-based cohort study.
Setting. Nationwide from all Departments of Medicine and Endocrinology in Sweden.
Subjects. A total of 312 young (15-34 years old) adults diagnosed with diabetes during 1987-88.
Main outcome measure. Plasma connecting peptide (C-peptide) 8 years after diagnosis. Preserved beta-cell function was defined as measurable C-peptide levels. Three islet antibodies - cytoplasmic islet cell antibodies (ICA), glutamic acid decarboxylase... (More) - Objectives. To establish the prevalence of remaining beta-cell function 8 years after diagnosis of diabetes in young adults and relate the findings to islet antibodies at diagnosis and 8 years later.
Design. Population-based cohort study.
Setting. Nationwide from all Departments of Medicine and Endocrinology in Sweden.
Subjects. A total of 312 young (15-34 years old) adults diagnosed with diabetes during 1987-88.
Main outcome measure. Plasma connecting peptide (C-peptide) 8 years after diagnosis. Preserved beta-cell function was defined as measurable C-peptide levels. Three islet antibodies - cytoplasmic islet cell antibodies (ICA), glutamic acid decarboxylase antibodies and tyrosine phosphatase antibodies - were measured.
Results. Amongst 269 islet antibody positives (ab+) at diagnosis, preserved beta-cell function was found in 16% (42/269) 8 years later and these patients had a higher body mass index (median 22.7 and 20.5 kg m-2, respectively; P = 0.0003), an increased frequency of one islet antibody (50 and 24%, respectively; P = 0.001), and a lower prevalence of ICA (55 and 6%, respectively; P = 0.007) at diagnosis compared with ab+ without remaining beta-cell function. Amongst the 241 patients without detectable beta-cell function at follow-up, 14 lacked islet antibodies, both at diagnosis and at follow-up.
Conclusions. Sixteen per cent of patients with autoimmune type 1 diabetes had remaining beta-cell function 8 years after diagnosis whereas 5.8% with beta-cell failure lacked islet autoimmunity, both at diagnosis and at follow-up. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/120623
- author
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Internal Medicine
- volume
- 255
- issue
- 3
- pages
- 384 - 391
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000188892500010
- pmid:14871463
- scopus:9244220717
- ISSN
- 1365-2796
- DOI
- 10.1046/j.1365-2796.2003.01273.x
- language
- English
- LU publication?
- yes
- id
- c35f3e59-d78a-4cda-80b0-c537637612d4 (old id 120623)
- date added to LUP
- 2016-04-01 16:55:16
- date last changed
- 2022-02-28 00:32:34
@article{c35f3e59-d78a-4cda-80b0-c537637612d4,
abstract = {{Objectives. To establish the prevalence of remaining beta-cell function 8 years after diagnosis of diabetes in young adults and relate the findings to islet antibodies at diagnosis and 8 years later.<br/><br>
<br/><br>
Design. Population-based cohort study.<br/><br>
<br/><br>
Setting. Nationwide from all Departments of Medicine and Endocrinology in Sweden.<br/><br>
<br/><br>
Subjects. A total of 312 young (15-34 years old) adults diagnosed with diabetes during 1987-88.<br/><br>
<br/><br>
Main outcome measure. Plasma connecting peptide (C-peptide) 8 years after diagnosis. Preserved beta-cell function was defined as measurable C-peptide levels. Three islet antibodies - cytoplasmic islet cell antibodies (ICA), glutamic acid decarboxylase antibodies and tyrosine phosphatase antibodies - were measured.<br/><br>
<br/><br>
Results. Amongst 269 islet antibody positives (ab+) at diagnosis, preserved beta-cell function was found in 16% (42/269) 8 years later and these patients had a higher body mass index (median 22.7 and 20.5 kg m-2, respectively; P = 0.0003), an increased frequency of one islet antibody (50 and 24%, respectively; P = 0.001), and a lower prevalence of ICA (55 and 6%, respectively; P = 0.007) at diagnosis compared with ab+ without remaining beta-cell function. Amongst the 241 patients without detectable beta-cell function at follow-up, 14 lacked islet antibodies, both at diagnosis and at follow-up.<br/><br>
<br/><br>
Conclusions. Sixteen per cent of patients with autoimmune type 1 diabetes had remaining beta-cell function 8 years after diagnosis whereas 5.8% with beta-cell failure lacked islet autoimmunity, both at diagnosis and at follow-up.}},
author = {{Schölin, A. and Björklund, Lars and Borg, H. and Arnqvist, H. and Björk, E. and Blohmé, G. and Bolinder, J. and Eriksson, J. W. and Gudbjörnsdottir, S. and Nyström, L. and Ostman, J. and Karlsson, A. F. and Sundkvist, Göran}},
issn = {{1365-2796}},
language = {{eng}},
number = {{3}},
pages = {{384--391}},
publisher = {{Wiley-Blackwell}},
series = {{Journal of Internal Medicine}},
title = {{Islet antibodies and remaining beta-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide Diabetes Incidence Study in Sweden.}},
url = {{https://lup.lub.lu.se/search/files/4819516/623956.pdf}},
doi = {{10.1046/j.1365-2796.2003.01273.x}},
volume = {{255}},
year = {{2004}},
}